SEP 23, 2019 2:31 PM PDT

Peptide-Based Therapeutics Advances Alzheimer Disease Research

WRITTEN BY: Nouran Amin

Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasculopathy. A defining feature of AD is the presence of a protein known as amyloid beta (Aβ) that clumps up into amyloid plaques.

These plaques affect memory and cognitive functions and progressive accumulation of the protein is toxic leading to neurodegeneration. Past clinical studies have focused on decreasing the levels of Aβ, through possible developments of Aβ vaccine-based therapies. However, current approved therapeutics do not work to alter the pathology of AD in it patients.

Now, recent research published by researchers in the University of Alberta, shows that a short sequence peptide fragment known as AC253 provides neuroprotective properties against Aβ toxicity in model mice. When a variant of this fragment is administered systemically, it was shown to improve spatial memory and learning in mice as well as attenuating plaque accumulation and inflammation in the brain. Future drug development based on this peptide will advance how to tackle AD disease progression.

“This has been 15, 20 years of painstaking and incremental work,” says University of Alberta Distinguished University Professor and neurologist Jack Jhamandas. “And it's like building a house: you put one brick down, then you put another brick on top of that, and pretty soon you have a foundation and then you have a house.

Learn more about current therapeutic advances in Alzheimer’s Disease (AD):

“In the mice that received the drugs, we found less amyloid plaque buildup and a reduction in brain inflammation,” said Jhamandas, who is also a member of the Neuroscience and Mental Health Institute. “So this was very interesting and exciting because it showed us that not only was memory being improved in the mice, but signs of brain pathology in Alzheimer’s disease were also greatly improved. That was a bit of a surprise for us.”

Via Folio.ca: U of A neurologist Jack Jhamandas led a team that found a new treatment significantly improved memory in mice with Alzheimer's disease. The researchers are now developing a drug that could eventually be used to treat human patients. (Photo: Jordan Carson)

The research brings a new outlook on peptide-based therapeutics and their potential in disease pathology. The study uses cell-based peptide library screening to demonstrate how peptide fragments based on AC253 sequence work to improve pharmacokinetics. Drugs based on this sequence have the potential to cross the blood-brain barrier in the central nervous system, and reverse spatial memory deficits in transgenic AD mice.

Findings of the study were published Scientific Reports by Nature Research.

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
AUG 11, 2022
Clinical & Molecular DX
New Tuberculosis Vaccine Enters Phase III Clinical Trial
AUG 11, 2022
New Tuberculosis Vaccine Enters Phase III Clinical Trial
Tuberculosis is a disease caused by the bacterium Mycobacterium tuberculosis. It is spread through the air when a person ...
SEP 14, 2022
Drug Discovery & Development
Media Survey Panel vs. Media Screen
SEP 14, 2022
Media Survey Panel vs. Media Screen
Media Survey Panel vs. Media Screen: An Interview with R&D Scientist Catherine Nguyen on Benefit of Using a Media Survey ...
AUG 16, 2022
Neuroscience
Phone Therapy Shows Promise for Treating Tinnitus
AUG 16, 2022
Phone Therapy Shows Promise for Treating Tinnitus
 A phone-based therapy has shown encouraging results in treating tinnitus in a recent clinical trial. The correspon ...
SEP 20, 2022
Microbiology
Manuka Honey Helps Treat Drug Resistant Lung Infections
SEP 20, 2022
Manuka Honey Helps Treat Drug Resistant Lung Infections
Drug resistant bacterial infections are expected to increase, and these dangerous illnesses already claim the lives of t ...
OCT 03, 2022
Plants & Animals
Yeast Proteins Could Provide Clues for New Antifungal Development
OCT 03, 2022
Yeast Proteins Could Provide Clues for New Antifungal Development
Yeast, like bacteria, causes infections. In fact, yeasts are responsible for over 100 million infections every year. The ...
OCT 01, 2022
Drug Discovery & Development
Capsule-based Fecal Microbiota Transplant Treats Clostridiodes Difficile Infection
OCT 01, 2022
Capsule-based Fecal Microbiota Transplant Treats Clostridiodes Difficile Infection
Oral treatment with Fecal Microbiota Transplant (FMT) via capsules containing freeze-dried microbes has similar effects ...
Loading Comments...